{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:57:41Z","timestamp":1794095861075,"version":"4.8.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.autrev.2023.103410","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T06:47:58Z","timestamp":1692341278000},"page":"103410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Immune-mediated inflammatory diseases: Common and different pathogenic and clinical features"],"prefix":"10.1016","volume":"22","author":[{"given":"Giovanni","family":"Monteleone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Moscardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Marafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.autrev.2023.103410_bb0005","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2023.103410_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102574","article-title":"How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: an expert opinion","volume":"19","author":"Sarzi-Puttini","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103410_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.091462","article-title":"Pathophysiology and pathogenesis of immune-mediated inflammatory diseases: commonalities and differences","volume":"85","author":"Rahman","year":"2010","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2023.103410_bb0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical skin reactions to biologics in patients with rheumatologic disorders","volume":"10","author":"Garcovich","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2023.103410_bb0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3899\/jrheum.091461","article-title":"Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities","volume":"85","author":"El-Gabalawy","year":"2010","journal-title":"J Rheumatol Suppl"},{"issue":"47","key":"10.1016\/j.autrev.2023.103410_bb0030","doi-asserted-by":"crossref","first-page":"6866","DOI":"10.3748\/wjg.v25.i47.6866","article-title":"Epidemiology of inflammatory bowel disease in South America: A systematic review","volume":"25","author":"Selvaratnam","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"21 Suppl","key":"10.1016\/j.autrev.2023.103410_bb0035","article-title":"Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs","volume":"8","author":"Williams","year":"2002","journal-title":"Am J Manag Care"},{"issue":"1","key":"10.1016\/j.autrev.2023.103410_bb0040","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.autrev.2023.103410_bb0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2023.103410_bb0050","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2023.103410_bb0055","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.autrev.2023.103410_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2023.103410_bb0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41584-020-00552-4","article-title":"Axial spondyloarthritis: concept, construct, classification and implications for therapy","volume":"17","author":"Robinson","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103410_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cei.13101","article-title":"Genetics of immune-mediated inflammatory diseases","volume":"193","author":"David","year":"2018","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103410_bb0075","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/ecco-jcc\/jjab048","article-title":"Results of the seventh scientific workshop of ECCO: precision medicine in IBD-prediction and prevention of inflammatory bowel disease","volume":"15","author":"Torres","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"Suppl4","key":"10.1016\/j.autrev.2023.103410_bb0080","article-title":"Genetics and the axial spondyloarthritis spectrum","volume":"59","author":"Brown","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2023.103410_bb0085","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.33415","article-title":"HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype","volume":"64","author":"Winchester","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2023.103410_bb0090","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.1780301102","article-title":"The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis","volume":"30","author":"Gregersen","year":"1987","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2023.103410_bb0095","first-page":"518","article-title":"Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn\u2019s disease","volume":"30","author":"Steer","year":"2003","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0100","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/mi.2011.29","article-title":"NOD2, an intracellular innate immune sensor involved in host defense and Crohn\u2019s disease","volume":"4","author":"Strober","year":"2011","journal-title":"Mucosal Immunol"},{"issue":"6837","key":"10.1016\/j.autrev.2023.103410_bb0105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35079107","article-title":"Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn\u2019s disease","volume":"411","author":"Hugot","year":"2001","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.autrev.2023.103410_bb0110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/gast.2002.34155","article-title":"Lack of common NOD2 variants in Japanese patients with Crohn\u2019s disease","volume":"123","author":"Inoue","year":"2002","journal-title":"Gastroenterology."},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0115","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.immuni.2014.12.010","article-title":"NOD1 and NOD2: signaling, host defense, and inflammatory disease","volume":"41","author":"Caruso","year":"2014","journal-title":"Immunity."},{"issue":"2","key":"10.1016\/j.autrev.2023.103410_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.it.2010.12.007","article-title":"The ever-expanding function of NOD2: autophagy, viral recognition, and T cell activation","volume":"32","author":"Shaw","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2023.103410_bb0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JIR.S137606","article-title":"NOD2 and inflammation: current insights","volume":"11","author":"Negroni","year":"2018","journal-title":"J Inflamm Res"},{"issue":"3","key":"10.1016\/j.autrev.2023.103410_bb0130","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/gast.2002.35393","article-title":"Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn\u2019s disease","volume":"123","author":"Abreu","year":"2002","journal-title":"Gastroenterology."},{"issue":"7","key":"10.1016\/j.autrev.2023.103410_bb0135","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/art.39619","article-title":"Replication of associations of genetic loci outside the HLA region with susceptibility to anti-cyclic citrullinated peptide-negative rheumatoid arthritis","volume":"68","author":"Viatte","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103410_bb0140","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2011-201225","article-title":"Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients","volume":"71","author":"Viatte","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2023.103410_bb0145","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1002\/art.39760","article-title":"Association between genetic variation in FOXO3 and reductions in inflammation and disease activity in inflammatory polyarthritis","volume":"68","author":"Viatte","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0150","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1053\/gast.2000.20258","article-title":"Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL","volume":"119","author":"de la Concha","year":"2000","journal-title":"Gastroenterology."},{"issue":"4","key":"10.1016\/j.autrev.2023.103410_bb0155","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/BOR.0000000000000720","article-title":"MHC class I associations beyond HLA-B27: the peptide binding hypothesis of psoriatic arthritis and its implications for disease pathogenesis","volume":"32","author":"Winchester","year":"2020","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103410_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04139.x","article-title":"The \u2018hygiene hypothesis\u2019 for autoimmune and allergic diseases: an update","volume":"160","author":"Okada","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2023.103410_bb0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.091462","article-title":"Pathophysiology and pathogenesis of immune-mediated inflammatory diseases: commonalities and differences","volume":"85","author":"Rahman","year":"2010","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2023.103410_bb0170","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3389\/fmicb.2016.01081","article-title":"The gut microbiota in immune-mediated inflammatory diseases","volume":"7","author":"Forbes","year":"2016","journal-title":"Front Microbiol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103410_bb0175","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/jcm8091309","article-title":"Rheumatoid arthritis-associated mechanisms of porphyromonas gingivalis and aggregatibacter actinomycetemcomitans","volume":"8","author":"G\u00f3mez-Ba\u00f1uelos","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2023.103410_bb0180","doi-asserted-by":"crossref","first-page":"1007165","DOI":"10.3389\/fimmu.2022.1007165","article-title":"Gut microbiota and rheumatoid arthritis: from pathogenesis to novel therapeutic opportunities","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103410_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.733992","article-title":"The gut microbiota in inflammatory bowel disease","volume":"12","author":"Qiu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"43","key":"10.1016\/j.autrev.2023.103410_bb0190","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2023.103410_bb0195","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01202","article-title":"Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis","volume":"2","author":"Scher","year":"2013","journal-title":"Elife."},{"issue":"8","key":"10.1016\/j.autrev.2023.103410_bb0200","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1172\/JCI93450","article-title":"Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints","volume":"127","author":"Pianta","year":"2017","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.autrev.2023.103410_bb0205","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1365-2133.2003.05552.x","article-title":"Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study","volume":"149","author":"Gudjonsson","year":"2003","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103410_bb0210","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2009.07.008","article-title":"Psoriasis--as an autoimmune disease caused by molecular mimicry","volume":"30","author":"Valdimarsson","year":"2009","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103410_bb0215","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2340\/00015555-2562","article-title":"Patient-reported outcomes and clinical response in patients with moderate-to-severe plaque psoriasis treated with tonsillectomy: A randomized controlled trial","volume":"97","author":"Thorleifsdottir","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0220","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3892\/etm.2021.9999","article-title":"Infection-provoked psoriasis: induced or aggravated (review)","volume":"21","author":"Teng","year":"2021","journal-title":"Exp Ther Med"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0225","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jdv.14051","article-title":"Periodontitis and risk of psoriasis: a systematic review and meta-analysis","volume":"31","author":"Ungprasert","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0230","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.berh.2014.10.018","article-title":"The role of the gut and microbes in the pathogenesis of spondyloarthritis","volume":"28","author":"Asquith","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"Suppl. 5","key":"10.1016\/j.autrev.2023.103410_bb0235","doi-asserted-by":"crossref","first-page":"S446","DOI":"10.1093\/infdis\/jiw362","article-title":"Chikungunya pathogenesis: from the clinics to the bench","volume":"214","author":"Gasque","year":"2016","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.autrev.2023.103410_bb0240","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1084\/jem.20160792","article-title":"Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor","volume":"213","author":"Tan","year":"2016","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.autrev.2023.103410_bb0245","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/2050640619876787","article-title":"The gut virome in inflammatory bowel disease pathogenesis: from metagenomics to novel therapeutic approaches","volume":"7","author":"Ungaro","year":"2019","journal-title":"United Eur Gastroenterol J"},{"issue":"4","key":"10.1016\/j.autrev.2023.103410_bb0250","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.MIB.0000440613.83703.4a","article-title":"Decoding norovirus infection in Crohn\u2019s disease","volume":"20","author":"Chamaillard","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"13","key":"10.1016\/j.autrev.2023.103410_bb0255","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.3390\/ijms23136955","article-title":"Roles of infection in psoriasis","volume":"23","author":"Zhou","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0260","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.berh.2014.10.009","article-title":"The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it","volume":"28","author":"Jacques","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0265","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/ard.2003.013599","article-title":"Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA\/1 mice: a model of psoriatic arthritis","volume":"63","author":"Lories","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2023.103410_bb0270","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","article-title":"Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells","volume":"73","author":"Jacques","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2023.103410_bb0275","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2009.120899","article-title":"Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke","volume":"70","author":"K\u00e4llberg","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0280","first-page":"820","article-title":"Smokers and nonsmokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database","volume":"28","author":"Naranjo","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103410_bb0285","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41586-022-05299-4","article-title":"Gut bacteria alleviate smoking-related NASH by degrading gut nicotine","volume":"610","author":"Chen","year":"2022","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.autrev.2023.103410_bb0290","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/apt.15774","article-title":"Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms","volume":"51","author":"Papoutsopoulou","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0295","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103410_bb0300","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"ECCO. 3rd European evidence-based consensus on the diagnosis and management of crohn\u2019s disease 2016: part 1: Diagnosis and Medical Management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0305","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/ecco-jcc\/jjaa254","article-title":"Food additive emulsifiers and their impact on gut microbiome, permeability, and inflammation: mechanistic insights in inflammatory bowel disease","volume":"15","author":"Bancil","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.autrev.2023.103410_bb0310","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jcmgh.2018.09.002","article-title":"The food additive maltodextrin promotes endoplasmic reticulum stress-driven mucus depletion and exacerbates intestinal inflammation","volume":"7","author":"Laudisi","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2023.103410_bb0315","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0320","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2021.06.049","article-title":"Obesity is associated with increased risk of Crohn\u2019s disease, but not ulcerative colitis: A pooled analysis of five prospective cohort studies","volume":"20","author":"Chan","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2023.103410_bb0325","first-page":"75","article-title":"Psoriasis and alcohol","volume":"9","author":"Svanstr\u00f6m","year":"2019","journal-title":"Psoriasis (Auckl)"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0330","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3390\/jcm9051387","article-title":"High frequency of undiagnosed psychiatric disorders in inflammatory bowel diseases","volume":"9","author":"Marafini","year":"2020","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.autrev.2023.103410_bb0335","first-page":"973","article-title":"Immune-mediated diseases from the point of view of psychoneuroimmunoendocrinology","volume":"11","author":"Ortega","year":"2022","journal-title":"Biology (Basel)"},{"issue":"13","key":"10.1016\/j.autrev.2023.103410_bb0340","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1016\/j.cell.2023.05.001","article-title":"The enteric nervous system relays psychological stress to intestinal inflammation","volume":"186","author":"Schneider","year":"2023","journal-title":"Cell."},{"key":"10.1016\/j.autrev.2023.103410_bb0345","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fpsyt.2019.00131","article-title":"Autoimmune diseases and psychotic disorders","volume":"10","author":"Jeppesen","year":"2019","journal-title":"Front Psych"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2023.103410_bb0350","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12026-014-8517-0","article-title":"Effects of stress on immune function: the good, the bad, and the beautiful","volume":"58","author":"Dhabhar","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2023.103410_bb0355","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/978-3-319-20215-0_14","article-title":"Effects of stress on commensal microbes and ImmuneSystem activity","volume":"874","author":"Gur","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.autrev.2023.103410_bb0360","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3389\/fimmu.2019.01696","article-title":"The role of inflammation in depression and fatigue","volume":"10","author":"Lee","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103410_bb0365","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/gut.2007.143453","article-title":"High frequency of early colorectal cancer in inflammatory bowel disease","volume":"57","author":"Lutgens","year":"2008","journal-title":"Gut."},{"issue":"4","key":"10.1016\/j.autrev.2023.103410_bb0370","article-title":"Prevalence of cancer in rheumatoid arthritis: epidemiological study based on the National Health and nutrition examination survey (NHANES)","volume":"12","author":"Bhandari","year":"2020","journal-title":"Cureus."},{"issue":"4","key":"10.1016\/j.autrev.2023.103410_bb0375","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: A systematic review and meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103410_bb0380","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/jid.2009.113","article-title":"Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis","volume":"129","author":"Brauchli","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103410_bb0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.14740\/gr740w","article-title":"IL-10 and IL-10 receptor mutations in very early onset inflammatory bowel disease","volume":"10","author":"Zhu","year":"2017","journal-title":"Gastroenterology Res"},{"issue":"3","key":"10.1016\/j.autrev.2023.103410_bb0390","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41588-018-0063-6","article-title":"Human TGF-\u03b21 deficiency causes severe inflammatory bowel disease and encephalopathy","volume":"50","author":"Kotlarz","year":"2018","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.autrev.2023.103410_bb0395","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/14712598.2019.1652267","article-title":"Inflammatory cytokines: from discoveries to therapies in IBD","volume":"19","author":"Marafini","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2023.103410_bb0400","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.3389\/fimmu.2019.02925","article-title":"TNF-\u03b1 directly enhances osteocyte RANKL expression and promotes osteoclast formation","volume":"10","author":"Marahleh","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103410_bb0405","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2147\/JIR.S288280","article-title":"Metalloproteinases in inflammatory bowel diseases","volume":"14","author":"Mar\u00f4nek","year":"2021","journal-title":"J Inflamm Res"},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0410","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/imt.10.67","article-title":"Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls","volume":"2","author":"Silva","year":"2010","journal-title":"Immunotherapy."},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0415","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology."},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0420","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for rheumatoid arthritis: a systematic review","volume":"36","author":"Mertens","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103410_bb0425","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0430","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X10378372","article-title":"The role of interleukin 6 in the pathophysiology of rheumatoid arthritis","volume":"2","author":"Srirangan","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"10.1016\/j.autrev.2023.103410_bb0435","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jid.2016.11.022","article-title":"IL-6 differs from TNF-\u03b1: unpredicted clinical effects caused by IL-6 blockade in psoriasis","volume":"137","author":"Blauvelt","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103410_bb0440","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/gutjnl-2017-314562","article-title":"Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn\u2019s disease (ANDANTE I and II)","volume":"68","author":"Danese","year":"2019","journal-title":"Gut."},{"issue":"10","key":"10.1016\/j.autrev.2023.103410_bb0445","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/ibd.21248","article-title":"IL-23\/IL-17 axis in IBD","volume":"16","author":"Sarra","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"Supplement_2","key":"10.1016\/j.autrev.2023.103410_bb0450","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjab185","article-title":"Blockade of IL-23: what is in the pipeline?","volume":"16","author":"Parigi","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.autrev.2023.103410_bb0455","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0460","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut."},{"key":"10.1016\/j.autrev.2023.103410_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614255","article-title":"Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis","volume":"12","author":"McGonagle","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0470","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5\u20136","key":"10.1016\/j.autrev.2023.103410_bb0475","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3109\/08830185.2013.823421","article-title":"Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad","volume":"32","author":"Troncone","year":"2013","journal-title":"Int Rev Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103410_bb0480","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2023.103410_bb0485","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/1744666X.2020.1679625","article-title":"Anti IL-17 in psoriasis","volume":"15","author":"Ly","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2023.103410_bb0490","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/ITT.S259126","article-title":"Anti-IL-17 agents in the treatment of axial spondyloarthritis","volume":"10","author":"Atzeni","year":"2021","journal-title":"Immunotargets Ther"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0495","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11926-021-00995-y","article-title":"Recent updates in the immunopathology of type 3 immunity-mediated enthesitis","volume":"23","author":"Nakamura","year":"2021","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"10.1016\/j.autrev.2023.103410_bb0500","doi-asserted-by":"crossref","first-page":"10305","DOI":"10.3390\/ijms241210305","article-title":"Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies","volume":"24","author":"S\u00e1nchez-Rodr\u00edguez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2023.103410_bb0505","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/CEG.S293272","article-title":"Anti-integrins for the treatment of inflammatory bowel disease: current evidence and perspectives","volume":"14","author":"Gubatan","year":"2021","journal-title":"Clin Exp Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0510","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2023.103410_bb0515","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211065329","article-title":"Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates","volume":"14","author":"Annese","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"978","key":"10.1016\/j.autrev.2023.103410_bb0520","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0525","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs."},{"issue":"13","key":"10.1016\/j.autrev.2023.103410_bb0530","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","author":"Harrington","year":"2020","journal-title":"J Inflamm Res"},{"issue":"3","key":"10.1016\/j.autrev.2023.103410_bb0535","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/ph15030270","article-title":"The use of Janus kinase inhibitors in axial spondyloarthritis: current insights","volume":"15","author":"Toussirot","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.autrev.2023.103410_bb0540","doi-asserted-by":"crossref","first-page":"1089099","DOI":"10.3389\/fmed.2023.1089099","article-title":"JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases","volume":"10","author":"Herrera-deGuise","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.autrev.2023.103410_bb0545","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001374","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0550","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/rheumatology\/keab740","article-title":"A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition","volume":"61","author":"McInnes","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103410_bb0555","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1756-185X.14246","article-title":"The association between elevated serum interleukin-22 and the clinical diagnosis of axial spondyloarthritis: A retrospective study","volume":"25","author":"Sagiv","year":"2022","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0560","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/art.37936","article-title":"Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin-23 signaling pathway in spondyloarthritis","volume":"65","author":"Coffre","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"9410","key":"10.1016\/j.autrev.2023.103410_bb0565","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet."},{"issue":"15","key":"10.1016\/j.autrev.2023.103410_bb0570","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2023.103410_bb0575","first-page":"1112","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized","volume":"71","author":"Mease","year":"2019","journal-title":"Control Phase III Trial Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103410_bb0580","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2023.103410_bb0585","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/rheumatology\/ken491","article-title":"Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis","volume":"48","author":"Blank","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2023.103410_bb0590","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103410_bb0595","doi-asserted-by":"crossref","DOI":"10.1177\/20406223231163110","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials","volume":"14","author":"Wang","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"issue":"8","key":"10.1016\/j.autrev.2023.103410_bb0600","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","article-title":"Efficacy of Bimekizumab and other biologics in moderate to severe plaque psoriasis: A systematic literature review and a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10370","key":"10.1016\/j.autrev.2023.103410_bb0605","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet."},{"issue":"10370","key":"10.1016\/j.autrev.2023.103410_bb0610","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet."},{"issue":"11","key":"10.1016\/j.autrev.2023.103410_bb0615","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103410_bb0620","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102832","article-title":"Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy","volume":"20","author":"Privitera","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"47","key":"10.1016\/j.autrev.2023.103410_bb0630","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.3748\/wjg.v28.i47.6743","article-title":"Role of the combination of biologics and\/or small molecules in the treatment of patients with inflammatory bowel disease","volume":"28","author":"Balderramo","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103410_bb0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054562","article-title":"Distinct profiles of effector cytokines mark the different phases of Crohn\u2019s disease","volume":"8","author":"Zorzi","year":"2013","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.autrev.2023.103410_bb0640","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103410_bb0645","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1038\/s41467-019-10769-x","article-title":"Conserved transcriptomic profile between mouse and human colitis allows unsupervised patient stratification","volume":"10","author":"Czarnewski","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2023.103410_bb0650","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2023.03.230","article-title":"Low-dose interleukin 2 for the treatment of moderate to severe ulcerative colitis","author":"Allegretti","year":"2023","journal-title":"Gastroenterology."},{"issue":"13","key":"10.1016\/j.autrev.2023.103410_bb0655","article-title":"Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103410_bb0660","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103410_bb0665","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103410_bb0670","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.30194","article-title":"Evaluation of the safety of ri-tuximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial","volume":"63","author":"Greenwald","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103410_bb0675","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific dual variable domain immunoglobu-lin targeting tumor necrosis factor and interleukin-17A, in patients with rheumatoid arthritis with an in-adequate response to methotrexate: a randomized, double-blind study","volume":"70","author":"Genovese","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103410_bb0680","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/annrheumdis-2018-214943","article-title":"Efficacy and safety of bimekizumab as add-on therapy for rheuma-toid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study","volume":"78","author":"Glatt","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10273","key":"10.1016\/j.autrev.2023.103410_bb0685","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.autrev.2023.103410_bb0690","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"10275","key":"10.1016\/j.autrev.2023.103410_bb0695","first-page":"670","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo-controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.autrev.2023.103410_bb0700","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103410_bb0705","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:28:56Z","timestamp":1761600536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223001441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":141,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1568997223001441"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103410","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-mediated inflammatory diseases: Common and different pathogenic and clinical features","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103410"}}